Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND SUPPLEMENTAL DISCLOSURES (Details Narrative)

v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND SUPPLEMENTAL DISCLOSURES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 20, 2022
Jan. 12, 2022
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Product Information [Line Items]              
Net loss     $ 6,374,000 $ 11,812,000 $ 13,363,000 $ 20,157,000  
Net cash used in operating activities         $ 11,002,000 13,620,000  
Common stock, par value     $ 0.0001   $ 0.0001   $ 0.0001
Warrants purchase     14,666,667   14,666,667    
Warrants exercise prices     $ 0.75   $ 0.75    
Repayments of Debt         $ 4,363,000 4,734,000  
Capitalized software development costs     $ 6,461,000   6,461,000   $ 4,348,000
Depreciation expenses     0 $ 0 0 $ 0  
FDIC Insured Amount     $ 250,000   $ 250,000    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member]              
Product Information [Line Items]              
Concentration risk, percentage     10.00% 10.00% 10.00% 10.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]              
Product Information [Line Items]              
Concentration risk, percentage         10.00%   10.00%
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor One [Member]              
Product Information [Line Items]              
Concentration risk, percentage     44.00% 30.00% 41.00% 28.00%  
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor One [Member]              
Product Information [Line Items]              
Concentration risk, percentage         41.00%   40.00%
Share-Based Payment Arrangement, Option [Member]              
Product Information [Line Items]              
Antidilutive securities         5,983,669 5,875,190  
Warrant [Member]              
Product Information [Line Items]              
Antidilutive securities         25,651,407 12,389,228  
Restricted Stock [Member]              
Product Information [Line Items]              
Antidilutive securities         2,199,388 2,751,508  
Common Stock Purchase Agreement [Member] | Tumim Stone Capital LLC [Member]              
Product Information [Line Items]              
Common stock, par value   $ 0.0001          
Shares issued, shares   607,287          
Common Stock Purchase Agreement [Member] | Tumim Stone Capital LLC [Member] | Maximum [Member]              
Product Information [Line Items]              
Shares issued, value   $ 50,000,000          
Securities Purchase Agreement [Member]              
Product Information [Line Items]              
Common stock, par value $ 0.0001            
Shares issued, shares 14,666,667            
Share Price $ 0.75            
Warrants purchase 14,666,667            
Warrants exercise prices $ 0.75            
Proceeds from issuance of warrants $ 11,000,000            
Repayments of Debt $ 1,650,000            
Securities Purchase Agreement [Member] | Series A Warrants [Member]              
Product Information [Line Items]              
Warrant, Exercise Price, Decrease $ 0.75            
Securities Purchase Agreement [Member] | Three Institutional Investors [Member]              
Product Information [Line Items]              
Debt instrument principal value   $ 6,300,000          
Securities Purchase Agreement [Member] | Maximum [Member] | Series A Warrants [Member]              
Product Information [Line Items]              
Warrants exercise prices 2.10            
Securities Purchase Agreement [Member] | Minimum [Member] | Series A Warrants [Member]              
Product Information [Line Items]              
Warrants exercise prices $ 1.10